secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0000950170-23-017919
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics Q1 net loss $46M; paltusotine Phase 3 PATHFNDR-1 data on track for Q3 2023
--------------------------------------------------------------------------------

- Net loss $46.0M for Q1 2023 vs $34.6M in Q1 2022; R&D expenses $38.5M, G&A $12.2M.
- Paltusotine PATHFNDR-1 (acromegaly) enrollment complete; topline data expected Q3 2023.
- PATHFNDR-2 enrollment target increased to up to 98; topline data expected Q1 2024.
- Phase 2 open-label study of paltusotine in carcinoid syndrome; preliminary data expected Q4 2023.
- CRN04777 Phase 2 study for congenital hyperinsulinism on clinical hold; additional info to be submitted to FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000095017023017919/0000950170-23-017919-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000095017023017919/crnx-20230504.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-017919

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer